New study prepares people with clotting gene mutations for future trials
NCT ID NCT07584265
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study enrolls 100 adults who have or may have Factor V Leiden or Prothrombin G20210A mutations, which increase blood clot risk. Participants get genetic testing and basic health checks like blood pressure and ECG to establish a health baseline. The goal is to help people learn about clinical research and prepare for future trials. Participation lasts about 10 weeks with 1-2 visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACTOR V LEIDEN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Richmond Pharmacology Limited
London, SE1 1YR, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.